Next Phase in Psychiatry? Or, NIMH Effort to Rescue Bad Drugs – WSJ

Next Phase in Psychiatry? Or, NIMH Effort to Rescue Bad Drugs – WSJ Fri, 29 Jul 2005 The Wall Street Journal uncritically reported: “The results of the largest studies ever conducted of depression and schizophrenia will be released in coming months, potentially transforming the way patients are treated and shaking…

FDA Public Health Advisory: SSRI-Suicide link in adults

FDA Public Health Advisory: SSRI-Suicide link in adults Wed, 20 Jul 2005 The American Medical Association is attempting to trivialize the hazards of prescribing SSRIs to children, urging physicians not to allow the evidence to interfere with their prescribing habits. See: http://www.ama-assn.org/ama/pub/category/print/15186.html The AMA has done the public a disservice…

Featured News

AHRP Speaks Out AHRP Press Briefing 9/14/04: Antidepressants & suicide-related risks for children Open Letter to NIMH re Prozac & Concealed Suicide Attempts Open Letter to Officials at NIMH AHRP Briefing 2/2/04: Scientists present suicide evidence Conflicts of Interest policy – New York Times Phase I Drug Trials Used Foster…

Pittman-Zoloft Trial to begin_ Another Boy on Prozac is Charged in Father’s Slaying – AP

Pittman-Zoloft Trial to begin_ Another Boy on Prozac is Charged in Father’s Slaying – AP Sun, 30 Jan 2005 The Associated Press reports about a homicide case (below) – this time involving a 10 year old boy who is charged with killing his father. AP reports that the child was…

Antidepressant warnings make experts nervous

http://www.mysanantonio.com/news/metro/stories/MYSA020305.13A.antidepressants.6d572159.htm Antidepressant warnings make experts nervous Web Posted: 02/03/2005 12:00 AM CST Marina Pisano San Antonio Express-News Even as warning labels about the risk of suicidality in children and teens taking antidepressants are going on medication labels, a new study is showing that American suicide rates have dropped significantly since…

Lilly Withdraws Duloxetine Application from FDA

Lilly Withdraws Duloxetine Application from FDA Fri, 28 Jan 2005 Eli Lilly and Boeringer Ingelheim have jointly announced that they have recinded their U.S. FDA Application for Duloxetine for Treatment of Stress Urinary Incontinence. http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=154081&print=yes Withdrawal of an application from FDA approval process is usually the result of the manufacturer’s…

Pfizer PainKiller Bextra withdrawn from market, New Boxed Warnings for Celebrex

Pfizer PainKiller Bextra withdrawn from market, New Boxed Warnings for Celebrex Thu, 07 Apr 2005 Pfizer’s withdrawal of the COX-2 pain reliever, Bextra, from the market because of potentially lethal side effects, including increased risk of cardiovascular malfunction and severe rash, validates Dr. David Graham’s analysis. This FDA medical expert…

FATAL FLAW Efforts to Overturn SSRI Black Box warning before it has even been implemented

FATAL FLAW Efforts to Overturn SSRI Black Box warning before it has even been implemented Date: Mon, 24 Jan 2005 Even as the Black Box Suicidality Warning on SSRI antidepressant labels have not even been implemented, aggressive efforts are underway by a powerful consortium of medical-pharmaceuticaql self-interest groups – among…

Former FDA Commissioner says FDA lost public trust

Former FDA Commissioner says FDA lost public trust Mon, 17 Oct 2005 The FDA’s failure to ensure drugs are properly tested in trials designed to detect serious adverse effects,  and the agency’s failure to require follow-up post-marketing studies to be reasonably secure in the knowledge that no lethal drugs are unleashed on the public has…